Immunotherapeutic drugs: growth forecast
The volume of the global market of drugs for immunotherapy will reach USD 73.5 billion by 2020
Weekly Pharmacy www.apteka.uaThe average annual growth rate of the global market of drugs for immunotherapy (including monoclonal antibodies, interferons-alpha, interleukins, vaccines, immune checkpoint inhibitors) in the period 2015-2020 will be 12.8%.
The maximum share in the total global sales of these drugs in monetary terms will be monoclonal antibodies. At the same time, the highest growth rates of sales volumes in monetary terms, according to forecasts, will show the market of immune checkpoint inhibitors. Both groups of drugs are targeted therapy drugs that selectively bind only to their target, identifying and attacking only cancer cells and practically not affecting normal ones.
One of the main growth factors is an increase in the incidence of oncological pathology. On the other hand, the high cost of innovative drugs used in oncology will be a deterrent to the growth of the market of drugs for immunotherapy.
Such data are presented in the report “Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis – Global Forecast to 2020” by the research company “MarketsandMarkets”.
The largest players in the market of immunotherapy drugs are pharmaceutical companies such as Amgen Inc. (USA), GlaxoSmithKline Plc. (UK), Merck & Co., Inc. (USA), Novartis International AG (Switzerland), and Roche Holding AG (Switzerland).
Portal "Eternal youth" http://vechnayamolodost.ru
03.12.2015